Description
EMWIN-L is an oral antidiabetic medicine from Arrowin Pharmaceuticals used for the management of Type-2 Diabetes Mellitus. It contains two medicines: Empagliflozin and Linagliptin, which work in different ways to help control blood sugar levels. Empagliflozin helps the kidneys to remove extra sugar from the body through urine, while Linagliptin helps the body to release insulin and improve blood sugar control.
Arrowin Pharmaceuticals offers EMWIN-L under its Medac-Cardiac & Diabetic division. Also, the product is available in 10/5 and 25/5 strengths and comes in 10 x 10 Alu-Alu tablet packaging.
What is EMWIN-L Tablet Used For?
EMWIN-L is an oral antibiotic medicine that is used to help manage Type 2 Diabetes Mellitus. It contains Empagliflozin and Linagliptin, which work in different ways to help control blood sugar levels. EMWIN-L tablet may be prescribed for:
- Type 2 Diabetes: Helps manage high blood sugar levels.
- Better Blood Sugar Control: Helps improve overall blood glucose control.
- Combination Treatment: May be used when more than one diabetes medicine is needed.
- Uncontrolled Blood Sugar: May be prescribed when diet, exercise, or other medicines do not provide adequate blood-sugar control.
- Long-Term Diabetes Management: Can be used along with a healthy diet and regular physical activity as directed by a doctor.
Working Mechanism of EMWIN-L Tablet
EMWIN-L contains Empagliflozin and Linagliptin. These two medicines work in different ways to help control blood sugar levels in people with Type 2 Diabetes.
Empagliflozin- SGLT2 Inhibitor
Empagliflozin is an SGLT2 inhibitor, which works through the kidneys by helping the body to remove extra sugar through urine. This helps to reduce the amount of sugar in the blood.
Linagliptin- DPP-4 Inhibitor
Linagliptin is a DPP-4 inhibitor, which helps the body to release more insulin when blood sugar is high and helps to control the release of glucagon, a hormone that can increase blood sugar.
Build Your PCD Pharma Franchise with Empagliflozin and Linagliptin Tablet
Empagliflozin and Linagliptin Tablet can be added to a Cardiac and Diabetic PCD pharma franchsie portfolio for the Type-2 Diabetes segment. Arrowin Pharmaceuticals offers a dedicated Cardiac Diabetic PCD Pharma Franchise range for pharma professionals, distributors, and entrepreneurs interested in the cardiac and diabetic market.
The Medace portfolio includes products from different categories, such as antidiabetic medicines, antihypertensives, lipid-management products, cardiac-care products, and nutraceuticals. For PCD franchise partners, Empagliflozin and Linagliptin Tablet can be a useful addition to a diabetes-focused product range, along with other suitable products based on market needs and product availability.
Benefits of EMWIN-L Tablet
- Combines two antidiabetic medicines that work in different ways.
- Helps support blood sugar control in Type 2 Diabetes.
- Empagliflozin helps remove excess sugar from the body through urine.
- Linagliptin helps the body regulate blood sugar and insulin release.
- Available as a convenient oral tablet.
- Available in different strengths to suit prescribed treatment needs.
- Can be used as part of a doctor-guided diabetes treatment plan.
- Can be added to a Cardiac & Diabetic pharmaceutical product portfolio.
